IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 13/05/2021 - Press release

    Hospital del Mar leads clinical trial of a new tool for detecting the sentinel lymph node in prostate cancer

    Hospital del Mar-IMIM is leading an international clinical trial to evaluate the performance and suitability of new equipment for locating the sentinel lymph node in prostate cancer patients. The new tool is a flexible, miniaturized probe, which should improve the detection of a marker (a radioactive molecule) injected into the patient to locate the first node the tumour drains to. The technology SENSEI®, has been developed by the UK company Lightpoint Medical with the support of the Hospital del Mar Urology Service.

    Més informació "Hospital del Mar leads clinical trial of a new tool for detecting the sentinel lymph node in prostate cancer"

  • 12/05/2021 - General information

    Dr. Clara Montagut to participate in the drafting of ESMO guidelines on the use of liquid biopsy in cancer patients

    Montagut has been invited to be part of the group of experts who will draft the European Society of Medical Oncology recommendations on the appropriate use of this technique and its implementation in clinical practice. The head of the Digestive Oncology section in the Medical Oncology Service at Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute (IMIM), Dr. Clara Montagut, will be a co-author of the ESMO recommendations for the use of liquid biopsy in cancer patients. The project is led by Professor Nicholas Turner, from the Institute of Cancer Research in London. The initiative is one of the tasks of the organisation's Translational Research and Precision Medicine Working Group.

    Més informació "Dr. Clara Montagut to participate in the drafting of ESMO guidelines on the use of liquid biopsy in cancer patients"

  • 29/04/2021 - General information

    The future of immunotherapy at the Optimizing Immunotherapy Congress

    The benchmark meeting in the field of immunotherapy cancer treatment was held once again, on April 9, in a hybrid format. This year, the presentations focused on the research and development of this type of treatment for various types of tumours, as well as molecular diagnostics. Understanding which factors make immunotherapy work in some cancer patients and not in others, the structure and genetics of tumours to help select the most appropriate treatment, is the current focus of research in this field. This was evident at the new edition of the Optimizing Immunotherapy, New Approaches, Biomarkers, Sequences and Combinations congress, held on 9 April in a hybrid format and organised by the Hospital del Mar Medical Research Institute (IMIM) and Hospital del Mar. The meeting brought together around twenty of the world's leading experts in research and clinical application of immunotherapy treatments to analyse the latest breakthroughs and the future of immunotherapy. It was backed by the SEOM, SOGUC and CIBERONC.

    Més informació "The future of immunotherapy at the Optimizing Immunotherapy Congress"

  • 22/04/2021 - General information

    Anna Bigas, one of the Top 100 Women Leaders in Spain

    Dr. Anna Bigas, coordinator of the Stem cells and cancer Research Group of the Hospital del Mar Medical Research Institute (IMIM) and scientific director of the CIBER Oncology has been chosen one of the Top 100 Women Leaders in Spain. This is a ranking created by Mujeres & Cia in 2011, an online magazine of reference among professional women that aims to make female talent visible and build a society based on equality. On the afternoon of April 21, the Top 100 Gala was held, this year in hybrid format, which was attended by Nadia Calviño, Second Vice President of the Government, soprano Pilar Navarro and TV presenter Sonsoles Onega. At the event, the chosen ones were announced, including Dr. Anna Bigas in the category of Academics, researchers and thinkers. Of the 100 chosen, 50 are chosen by a jury, 40 by Mujeres & Cia and 10 by the public through voting.

    Més informació "Anna Bigas, one of the Top 100 Women Leaders in Spain"

  • 13/04/2021 - General information

    Dr. Clara Montagut joins the faculty of the European Society of Medical Oncology (ESMO)

    The head of the Digestive Oncology section in the Medical Oncology Service at Hospital del Mar is taking on this new role in the ESMO Faculty until 2025. From now on, she will be part of the group of experts who collaborate with the organisation to fulfil its educational responsibilities. Dr. Clara Montagut is now a member of the ESMO Faculty, the teaching body of the European Society of Medical Oncology, specifically in the gastrointestinal, colon and rectal tumours group. The head of Digestive Oncology at Hospital del Mar and the clinical and translational research group laboratory for new therapies and biomarkers in colon and rectal cancer at the Hospital del Mar Medical Research Institute (IMIM), will form part of the group of experts from the organisation who offer advice and support to help the society fulfil its educational responsibilities.

    Més informació "Dr. Clara Montagut joins the faculty of the European Society of Medical Oncology (ESMO)"

  • 09/02/2021 - General information

    Anna Bigas, new Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research Institute

    Dr. Bigas has joined as Deputy Director of Preclinical Research at the Josep Carreras Institute, maintaining her relationship with the Hospital del Mar Medical Research Institute (IMIM), where she leads the Stem Cells and Cancer group. The new responsibility that Dr. Bigas assumes will serve to enhance coordination between all groups in the institute that do basic and translational research, seeking synergies between them and optimizing their research, as well as to enhance the existing collaboration between the professionals of our institute and those of the IMIM. In the last ten years, as head of the Stem Cells and Cancer group, she has studied the molecular and physiological processes of stem cells in different tissues, in order to draw similarities with the appearance and progression of cancerous processes. In particular, her research focuses on the study of hematopoietic stem cells, responsible for the formation of blood cells, in order to understand the process of leukemia and develop strategies to fight against this disease.Currently, her research group is working on the identification of epigenetic and gene expression profiles, which allow discovering new therapeutic targets not yet exploited clinically.

    Més informació "Anna Bigas, new Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research Institute"

  • 20/01/2021 - General information

    The role of interferons in tumour cell resistance to immunotherapy

    The Journal of Clinical Investigation has published a review authored by Michelle von Locquenghien, Catalina Rozalén, and Toni Celià-Terrassa, all members of the Cancer Stem Cells & Metastasis Dynamics Lab at the Hospital del Mar Medical Research Institute (IMIM). In the article, they analyse current knowledge on the role of interferons -cytokines (proteins) involved in regulating the function of immune system cells- in the mechanisms that allow tumour cells to develop treatment resistance. The authors explain how the relationship between tumour cells and the immune system evolves as the cancer progresses, causing these cells to acquire systems that enable them to resist attack. They point out that the principal mechanisms used to achieve this are related to interferon signalling. In this respect, they highlight new evidence supporting immunotherapy-mediated immunoediting and show how interferons can impact either treatment response or resistance. All these factors lead the authors to support its potential as a therapeutic strategy in cancer.

    Més informació "The role of interferons in tumour cell resistance to immunotherapy"

  • 16/12/2020 - Press release

    Cancer cells resistant to treatment are already present before diagnosis of adult leukaemia

    T-cell acute lymphoblastic leukaemia (T-ALL) is a cancer of the blood that affects mainly children, but also less frequently adults. In adults, although the response to treatment might be initially positive, relapses are common and have a poor prognosis. A collaborative project between IRB Barcelona's Biomedical Genomics lab, headed by ICREA researcher Núria López-Bigas, Anna Bigas' group at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), and Josep Maria Ribera's lab at the Josep Carreras Leukaemia Research Institute (IJC) has discovered that the cells responsible for resistance to T-ALL treatment in adults are already present in the tumours before diagnosis.

    Més informació "Cancer cells resistant to treatment are already present before diagnosis of adult leukaemia"

  • 25/11/2020 - Institutional news

    Strategic alliance with the Josep Carreras Foundation for research into haematology

    The Hospital del Mar Medical Research Institute (IMIM) and the Josep Carreras Leukaemia Research Institute (IJC) have signed a collaboration agreement with the aim of jointly promoting scientific research, teaching and training personnel in the healthcare field, as well as pooling their efforts to efficiently manage public and/or private resources available for biomedical research activities in the field of haematology-oncology.

    Més informació "Strategic alliance with the Josep Carreras Foundation for research into haematology"

  • 30/11/2020 - General information

    Dr. María Martínez, new president of the Spanish Neuro-Oncology Research Group

    Dr. Dr. María Martínez, head of the neuro-oncology section of the Medical Oncology Service at Hospital del Mar and a researcher in the Cancer Molecular Therapy research group at the Hospital del Mar Medical Research Institute, will chair the Spanish Neuro-Oncology Research Group (Grupo Español de Investigación en Neurooncología; GEINO) for the next two years. Her appointment was confirmed on 27th November at the organisation's assembly, which was held virtually. Dr. Martínez explained that her objective at the head of GEINO is "To maintain and strengthen the execution of clinical trials in neuro-oncology, both for primary central nervous system tumours and brain metastases, and to continue down the same path as the previous chairmanship with regard to the most basic and translational researchers, as well as to build bridges and collaborate with other cooperative groups".

    Més informació "Dr. María Martínez, new president of the Spanish Neuro-Oncology Research Group"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact